Working to improve your health

20 NOVEMBER 2025

FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2025

AFT delivers 10th consecutive first half revenue increase

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 33% over 1H 25 to reach a record $114.9 million as its investments for growth deliver.

Growth — the 10th consecutive period of first half-year revenue increasing against the same period of the prior year since listing on the NZX — was led by Australia and was supported by the strong performance of Asian and International markets, which have now fully recovered from the one-off disruptions in 1H 25.

AFT continues to make good progress advancing the development of our International business hubs in markets that share similar characteristics with its highly successful Australasian operations. It has also advanced the company's research and development (R&D) portfolio, and its active out and in-licensing programs which continue to position the company for long term growth.

AFT remains focused on delivering against its target of $300 million revenue for the FY 27 financial year, while balancing disciplined investment to support long-term value creation.

HIGHLIGHTS

- Half-year operating revenue rises 33% to $114.9 million[1], reflecting strong growth in Australia, the benefits of a recovery from the one-off disruptions of 1H 25 and strong growth in Asia and International markets
- EBITDA[2] of $6.6 million and operating profit of $4.7 million up from prior period losses amid ongoing investment in International business hubs and R&D. Net profit after tax of $2.7 million

[1] All comparisons are to the six months to 30 September 2024 unless otherwise stated.
[2] EBITDA is a non-GAAP measure of performance. It is defined and reconciled to GAAP measures on page [XX] of the investor presentation released to the NZX and ASX today.

- Balance sheet remains strong with net debt of $20.9 million[3] within target range
- Licensing: multiple out-licensing agreements executed in the period; pipeline of further agreements and term sheets progressing, including the licensing of our novel IV iron formulation in China
- R&D: positive progress across late-stage assets, including the IV iron programme, antibiotic eyedrop and topical strawberry birthmark candidates
- Outlook: on track to deliver FY 26 operating profit guidance of $20 million to $24 million and to further advance the multi-year growth strategy

A video of AFT Pharmaceuticals Co-Founder and Managing Director Dr Hartley Atkinson discussing these results can be found at the following link: https://youtu.be/1o4LxkcAQ9g

AFT Pharmaceuticals Chair David Flacks said: "This first-half result demonstrates continued execution against our strategy and the impact of a return to normalised trading conditions in Asia and in our international business.

"We have continued to invest in the portfolio and in our international platforms to support a larger, more diversified and resilient AFT. That focus — on disciplined growth and long-term value creation — remains unchanged as we progress towards our FY27 revenue target of $300 million."

Dr Atkinson said: "We have seen solid performance across all regions with results being particularly pleasing in our largest market, Australia. I am also delighted with the progress we are making in our International markets and in the development our own innovative intellectual property.

"We expect our business hubs in the United Kingdom and South Africa to begin to contribute to earnings in the second half of the year, validating the potential we see in these markets and our investment in them.

"We meanwhile are seeing continuing strong interest in our development portfolio with an out-licensing agreement for our novel iron therapy secured in China, the worlds' second largest pharma market after the end of the period. We are excited about the expanding prospects for our company."

FINANCIAL PERFORMANCE

Revenue grew by 33% to $114.9 million from $86.7 million in 1H 25. Growth was driven by the Australian business, up 31% to $66.5 million with solid performances across key OTC and pharmacy brands and continued uptake in prescription medicines.

[3] This figure excludes related party loans

It was also supported by an improving contribution from the International business (up 133% to $12.9 million) and Asia (up 69% to $7.5 million) as the one-off factors that affected 1H25 trading — a doctors' strike in Korea and international customer de-stocking — were resolved in 2H 25.

Gross margin was 43.2%, reflecting a small increase in margin from product sales and royalties and $1.8m additional license income on commercial sales.

Operating expenses increased 18% as the company continued to fund growth initiatives from its own resources, including: (i) start-up and scaling costs for the business hubs in North America, the UK/Europe and South Africa; (ii) brand and market entry investments to support recent and upcoming launches; and (iii) higher R&D expenses to advance late-stage projects.

The resulting operating profit was $4.7 million, up $6.5 million from a $1.8 million loss in 1H 25. EBITDA was $6.6 million, up $7.3 million from a $0.7 million loss in 1H 25. Net profit after tax was $2.7 million from a $2.5 million loss in 1H 25.

Further information on the performance in the regions is provided in the FY 26 Interim Report and Investor Presentation released in conjunction with these results.

RESEARCH AND DEVELOPMENT

R&D expenditure (expensed and capitalised) in the half year was $9.5 million up from $8.9 million in 1H 25 as we advanced a diversified portfolio of development projects spanning pain, dermatology and eyecare. We also made notable progress across several late-stage programmes:

- Intravenous iron: Following the positive Phase III trial, AFT and its development partners are now preparing to commence a large global Phase III confirmatory study of ~1,000 patients. Two additional patent applications have been filed to further protect the asset.
- Antibiotic eyedrop: The pre-IND application[4] has been filed with the US FDA, with IND submission targeted early next financial year to enable first-in-human studies. The product seeks to address drug-resistant ocular infections for which registered therapies are limited. Current treatments are primarily prepared by compounding pharmacies which is not desirable, especially for eyecare products where full GMP sterility is a crucial factor.
- Topical strawberry birthmarks: The pre-IND has been prepared and filed; FDA feedback has been received which guides the IND submission pathway and Phase I, II and III study designs.
- Maxigesic IV paediatric: We are preparing to commence a Maxigesic IV study for paediatric populations, following FDA approval of our paediatric study

[4] IND: Investigational New Drug application.

plan. Our medicine offers a new option for pain care in children, who have fewer safe and effective options for managing pain compared to adults, particularly in hospital settings.

We have progressed out-licensing discussions — securing five agreements in the 1H 26 period. A key achievement has been the out-licensing agreement for our novel IV iron therapy for China[5] which was secured after the 1H 26 period.

The agreement, with Chengdu-based Grand Life Sciences Group, a top five Chinese pharmaceutical company by sales revenue, features upfront, development and sales milestone payments as well as recurring royalties. This revenue will be shared between AFT and its development partners. Grand Life Sciences will also contribute to funding the global clinical development program.

We also advanced our in-licensing programme to deepen our product portfolio. A number of products in-licensed are now either in registration or are being prepared for regulatory filing. In many cases we have secured in-licensing across multiple territories to include the AFT business hubs, further advancing the leverage we gain from these activities.

Collectively, the R&D and business development programmes will support multiple launches over the next several years, broadening our product portfolio and increasing both the size and the diversity of revenue through direct sales and through licensing and royalty income.

INTERNATIONAL DEVELOPMENT

AFT continues to direct significant effort towards the development of sales in the international business hubs, which share the characteristics of our highly successful Australasian operations.

United Kingdom

We are pleased with the progress we are making in this market and expect operations to reach breakeven in the second half of this current financial year. We continue to focus upon growing the Combogesic tablets and IV brands.

A recent success has been the addition of Combogesic IV to the formulary of London Northwest University Healthcare NHS Trust. This trust covers Ealing Hospital and the Northwick Park Hospital, which hosts the UK's largest and busiest Accident and Emergency Department. A significant number of regulatory filings are underway for both AFT proprietary products and new products we have in-licensed to the UK, supporting a strong product launch pipeline.

[5] Licensing negotiations enabled by Ms Hong Xie, Pharma China Consulting

Canada:
We launched our first product, Combogesic IV in 1H 26 and we are planning additional launches in 2H 26. Our team, led by experienced Canadian pharma executive, Sylvain Desjeans, is now fully operational. We continue to work on a significant number of regulatory filings in the 2H 26 time period in order to further expand our product portfolio in Canada.

South Africa:
We accelerated our product launch schedule in this market from four to eighteen products in the latter part of this financial year with this increase related to acquiring some additional product licenses. This will significantly accelerate sales growth in the next financial year. The business is expected to start to contribute to group earnings in 2H 26. Our South African team is in place, led by experienced South African pharma executive, Deon Hall.

BALANCE SHEET

AFT remains well funded, with net debt of $20.9 million at 30 September 2025 ($18.9 million, 30 September 2024), within our target leverage range and reflecting continued investment in growth. Discussions on renewal of the banking facility are well advanced. Inventory was $58 million, managed prudently against normalising supply chains and the anticipated launches in the second half.

OUTLOOK

Consistent with prior years, AFT expects second half sales and earnings to be greater than the first half of FY 26 supported by a strong programme of launches in International markets, continued expansion in the Australasian portfolio, and increasing contributions from the company's international business hubs as they scale.

AFT remains focused on disciplined execution: converting R&D progress into value through clinical and regulatory milestones; advancing out-licensing to monetise our IP; and deepening in-licensing to add attractive, strategically aligned products in priority markets.

Our R&D and international expansion efforts come at the expense of short-term earnings, but they will support the extension of AFT's decades-long record of delivering uninterrupted growth and shareholder value creation. They will also deliver the product and geographic diversification that underpins the resilience of the business.

AFT remains on track to deliver a FY 26 operating profit within the previously outlined range of $20 million to $24 million. The company also reiterates its confidence in its pathway to $300 million annual revenue in FY 27, supported by

the launch schedule, our licensing programme, the scaling of international hubs and continued geographic expansion.

Released for and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer.

For more information

Investors
Dr Hartley Atkinson
Managing Director
AFT Pharmaceuticals
Tel: +64 9 488 0232

Media
Richard Inder
The Project
Tel: +64 21 645 643

About AFT Pharmaceuticals

AFT is a growing New Zealand-based multinational pharmaceutical company that develops, markets and distributes a broad portfolio of medicines across OTC, prescription and hospital channels. The portfolio comprises proprietary and in-licensed products across pain management, dermatology, eyecare, allergy, gastro and other categories. AFT commercialises products directly in Australia, New Zealand, Singapore, Malaysia, Hong Kong, the US, Canada, the EU (ex Ireland) and the UK, and out-licenses to partners in more than 125 countries.

For more information, visit www.aftpharm.com.

INVESTOR PRESENTATION

1H 2026 | 20 NOVEMBER 2025

Dr Hartley Atkinson
Managing Director

Malcolm Tubby
Chief Financial Officer

AFT pharmaceuticals

Working to improve your health

Important Notice

This presentation has been prepared by AFT Pharmaceuticals Limited ("AFT"), to provide a general overview of the performance of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient.

This presentation should be read in conjunction with AFT's interim financial statements, market releases and other periodic and continuous disclosure announcements, which are available at www.nzx.com and www.asx.com.au.

All amounts are disclosed in New Zealand dollars (NZ$) unless otherwise indicated.

All references to financial years appearing in this presentation are for the period ending 31 March, unless otherwise indicated. This presentation is not a recommendation, offer or invitation to acquire AFT's securities or other form of financial advice or disclosure document.

While reasonable care has been taken in compiling this presentation, none of AFT nor its subsidiaries, directors, employees, agents or advisers (to the maximum extent permitted by law) gives any warranty or representation (express or implied) of the accuracy, completeness or reliability of the information contained in it nor takes any responsibility for it.

The information in this presentation has not been and will not be independently verified or audited. This presentation may contain certain forward-looking statements and comments about future events, including with respect to the financial condition, results, operations and business of AFT.

These statements are based on management's current expectations, which may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and the actual events or results may differ materially and adversely from these statements. Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon (and is not) an indication of future performance.

Building the Foundation for the Next Phase of Growth

Fortifying AFT's Global Network to Address Un-met Need

CONTINUED STRENGTH IN ESTABLISHED ANZ BUSINESS

- 1H 26 Total Sales $114.9M
- ANZ Sales $94.5m, up 23% on 1H 25
- Growth focus with FY 27 $300m Turnover Target

EXPANDING GLOBAL FOOTPRINT

- Europe: UK & EU
- North America: USA & Canada
- Asia: China, Singapore, Malaysia & Hong Kong
- Africa: South Africa

DEVELOPING INNOVATIVE THERAPIES WITH R&D

- Active R&D pipeline of 8 patented products
- Progression of 24+ off-patent injectables
    - IP project
- Significant Global Market Opportunities

PRODUCT LAUNCHES DRIVING COMMERCIAL TRACTION

- 5 R&D programs currently being commercialized in multiple countries
- 5 agreements closed in 1H 26 and significant number of agreements in negotiation

AFT GLOBAL DISTRIBUTION PARTNERSHIPS

- Agreements in 100+ countries
- Sales in 85 countries

Growth Continues -10th Consecutive First Half Revenue Increase

KEY HIGHLIGHTS

- 1H 26 revenue increased, with growth led by Australia and supported by of Asian and International markets, which have now fully recovered from the one-off disruptions in 1H 25
- We have advanced the development of our International business hubs in markets that share similar characteristics with its highly successful Australasian operations; South Africa and the UK expected to contribute to earnings in 2H 26
- EBITDA up $6.6m from loss of $0.7m; Operating Profit of $4.7m from a loss of $1.8m in 1H 25 amid ongoing investment in business development and R&D
- Advancing our research and development programmes and focused on delivering our revenue target of $300m for FY 27



[1] EBITDA is a non-GAAP measure of financial performance and is defined and reconciled to NZ GAAP on page 22 of this presentation.
* FY20 Normalised to exclude $9.8m gain on de-recognition of equity accounted investment.

Australia: Ongoing Market Growth from Product and Sales Investments

- Revenues in Australia grew 31% to $66.5m from $50.8m in FY 24, lifted by strong growth across all channels
- Growth was led by eyecare, pain relief, and iron supplements and the company's broad portfolio of injectables
- Australian operating profit increased to $9.6m up from $4.0m in 1H 25, with consistent investments in sales and marketing spend





New Zealand: Steady Growth with Ongoing Opportunities

- Revenues in New Zealand grew 8% to $28.0m, up from $26.0m in 1H 25, led by allergy, dermatology, and eyecare
- Growth slower than other markets, but still offers considerable growth opportunities
- Operating profit improved to $4.1m, up from $3 million in 1H 25, driven by the revenue growth.





Asia: Strong Growth and Broadening Asia Coverage

- Revenues in Asia increased to $7.5m, up 69% from $4.4m after recovery in Maxigesic IV following the Korean doctors' strike; seeing growing sales in other markets
- Focusing on broadening our reach in Asian markets to build sales across the region
- Operating profit rises strongly on 1H 25 to $2.1m from $0.5 in line with the recovery in sales and business development investment





** Includes license income*

AFT's Global Reach

Our medicines are now available in 85 countries around the world



▲ Launched

▲ Launch Pending

International Expansion – Investing for Long Term Growth in New Markets

INTERNATIONAL REVENUE



COUNTRIES WHERE MAXIGESIC IS SOLD AND ORDERED



FY Product Sales & Royalties | 1H Product Sales & Royalties | 2H Product Sales & Royalties | Licence Income

- International revenue from product sales and royalties of $11m up 104% from $5.4m in 1H 25 as customers returned to more normal buying patterns, benefitting from sales growth and new product launches
- We expanded the territories in which products are sold or ordered to 85 up from 80 in March 2025 with launches including Egypt and Thailand
- Licensing of $1.9m up on $0.2m in 1H 25.
- Operating losses reduce to $4.4m from $4.6m in 1H 2025 despite continued R&D and investment in our business hubs in North America, the UK, Europe and South Africa

Progressing Expansion of AFT's Global Footprint

Expanding markets for our proprietary IP and in-licensed new products

AFT PHARM UK

- Combogesic tablets extended to >2500 stores (Boots, SuperDrug and independent pharmacies)
- Combogesic IV NHS formulary listings build momentum
- Expanding our product range with AFT IP and in-licensed products
- Expected to breakeven in 2H 26

AFT PHARM SOUTH AFRICA

- Hired CEO experienced in the hospital market
- Accelerated our FY 26 launch programme from 4 to 18 products
- Secured significant existing pipeline and expanding with significant pipeline of new products
- Expected to contribute to earnings in 2H 26

AFT PHARM CANADA

- Launched Combogesic IV; selected OTC offerings underway
- Hired CEO & small sales force
- Additional launches planned in 2H 26; significant launch pipeline

Progressing Expansion of AFT's Global Footprint

Expanding markets for our proprietary IP and in-licensed new products

AFT PHARM USA

- Selected OTC launches such as Collagen Liposachets and coordinate licensees and distributors
- Working closely with Hikma to realise the patient care benefits that come with following Combogesic IV with Combogesic Rapid

AFT PHARM EUROPE

- Licensing acquired products, AFT R&D products plus AFT Sinoject products
- Launches of acquired products underway this FY26

AFT PHARM HONG KONG

- Launching further selected AFT products
- A significantly expanding pipeline of new products

AFT PHARM SINGAPORE

- Extending into Private Hospital market
- Launching further selected AFT products
- A significantly expanding pipeline of new products

Progressing Research and Development Investments

Several programs have exited development and are moving to revenue generation; our R&D programme is also attracting interest

COMMERCIALISING AFT'S INTELLECTUAL PROPERTY

A significant number of licensing agreement discussions underway

Intravenous Iron Development Project - licensed to Chengdu-based Grand Life Sciences Group, includes development and sales milestone payments

- Sharing of development costs with AFT and our development partners
- Reinforces the value of our development portfolio

Maxigesic Multiple Dose Forms

- Rapid Dissolving Tablet (Patent 2039).
- Maxigesic Day/Night (AU patent 2035)
- Oral Liquid – additional formulation (Patent TBC). US file 1Q 27
- Dry Stick (Patent 2030). File 3Q 26
- IV & Pediatric IV (Patent 2031, 2035).
- US FDA has approved our pediatric study plan

Crystaderm – antibacterial and anti-acne cream, a proprietary formulation

Micolette – micro-enema for bowel obstruction

Kiwisoothe – tablets and sachets for gut discomfort and constipation

Capsaicin – cream in two strengths for Osteoarthritis (low) and Neuropathic pain (high)

RESEARCH AND DEVELOPMENT EXPENSES



*Expensed and capitalised

A Strong Research and Development Pipeline

AFT's positive cashflows have positioned the company well to undertake and secure research and development projects either alone or in partnership with others.

PROJECT	PATENTS	PARTNERS	FILING	PROGRESS/ MARKET /COMMENT
24 Hospital Injectables	Nil	Sinoject - AFT 70%	3Q 25 –> 1Q 27	AFT affiliate market US$450M. 3 dossiers ready in 2025
Migraine Project	Nil[1]	Sinoject - AFT 70%	1Q 27	Market US$180M (US$45M in AFT markets)
Pascomer PWS	2040 2044	AFT 100%	3-4Q 27	No approved treatment
Iron IV (NCE[3])	2032 2035	AFT - 45%	2-3Q 27	Market US$7.4Bill by 2033. Positive initial Phase III Study, Preparing Phase III confirmatory trial of ~1,000 patients
Antibiotic eye drop	2037 2044	AFT 100% IP in-licensed[4]	1-2Q 28	No approved treatment and compounded. Analyst estimate >US$1Bill market Pre-IND application filed with the US FDA; IND to be submitted 2Q 2026
Strawberry BMs Topical	2041 2044	AFT 100% IP in-licensed[4]	3-4Q 28	Market for orals US$650M by 2029 Pre-IND filed, FDA feedback received to guide IND submission and IND to be submitted 4Q 2026
Keloid Scars Topical	2041	AFT 100% IP in-licensed[4]	2-3Q 29	No approved treatment. Unapproved topicals market US$1.5Bill growing to $2Bill (2035) Formulation finalized and preparing for pre-IND submission
Burning Mouth	TBC[2]	AFT - 50%	1Q 30	No approved treatment. Testing market for BMS is US$464M (2023) and growing to US$805M (2033)
Vulvar Lichen Sclerosis	TBC[2]	AFT - 50%	1Q 30	No approved treatment. Market estimated to be >US$1Bill by 2037
NasoSURF	2036	AFT - 90%	Address dosing consistency	

[1]Improved delivery platform [2]Patents under development and to be filed [3]New Chemical Entity [4] Royalties and payments due for licensed IP

Gross Margin gains and investment in development

Six months to 30 September	2025 $000	Revenue %	2024 $000	Revenue %	△%
Revenue	114,942		86,713		33%
Gross profit	49,690	43.2%	36,199	41.7%	
Operating expenses and other income	(44,953)	39.1%	(38,002)	43.8%	18%
Operating profit	4,737		(1,803)		363%
Finance expenses and other income	(300)		(1,036)		
Tax	(1,713)		383		
Profit/(loss) after tax	2,724		(2,456)		211%
Revenue from product sales and royalties	113,004		86,545		30.6%
Gross profit from product sales and royalties	47,752	42.3%	36,031	41.6%	40.7%

- Revenue increased 33% lifted by a recovery from the disruptions of 1H 25 and continued strong growth led by the Australian business
- Gross Margin improved to 43.2% lifted by improvements in margins as well as increased license income
- Operating expenses increase 18% as we funded investments for growth
  - Start up and scaling costs for the business hubs
  - Brand and market entry investments
  - Increased research and development expenses
  - ERP migration to NetSuite

AFT is Well Funded – Well Positioned to Fund Growth Investments

Six months to 30 September	2025 $000	2024 $000	Δ%	FY 25 $000
Current assets (excluding cash)	94,882	76,090		97,232
Cash	12,099	10,686	13%	11,110
Non current assets	64,641	61,117		61,473
Total assets	171,622	147,893	16%	169,815
Current liabilities (excluding interest-bearing liabilities)	37, 777	31,916		43,256
Current interest-bearing liabilities	32,987	-		
Non current liabilities (excluding interest-bearing liabilities)	2,871	2,848		3,882
Non current interest-bearing liabilities	-	29,600		25,600
Total liabilities	73,635	64,364	14%	72,738
Total equity	97,987	83,529		97,077
Total liabilities and equity	171,622	147,893	16%	169,815

- Inventory of $58m managed prudently against the normalisation in trading conditions and anticipated launches in 2H 26
- Net debt at the end of September 2025 was $20.9m up from $18.9m a the end of September 2024.
- Discussions to renew our banking facility are well advanced

Growth Investment Underpinned by Ongoing Strong Cashflow

Six months to 30 September	2025 $000	2024 $000
Net cash from operating activities	476	4,353
Net cash used in investing activities	(3,495)	(3,939)
Net cash (used)/generated from financing activities	3,053	(1,582)
Net increase/(decrease) in cash	34	(1,168)
Impact of foreign exchange on cash and cash equivalents	68	(186)
Opening cash and cash equivalents	11,110	12,040
Closing cash and cash equivalents	11,212	10,686

- Continued investment into research and development projects to fuel long term growth
- End period cash holdings of $11.2 million

Outlook: Positioned to Drive Future Growth in Both Revenue and Earnings

- Consistent with prior years, we expect second half sales and earnings to be greater than the first half of FY26 supported by a strong programme of launches, continued expansion in the Australasian portfolio, and increasing contributions from the company's international business hubs as they scale
- Our R&D and international expansion efforts come at the expense of short-term earnings, but they will support the extension of AFT's decades-long record of delivering uninterrupted growth and shareholder value creation. They will also deliver the product and geographic diversification that underpins the resilience of the business
- AFT remains on track to deliver a FY26 operating profit within the previously outlined range of $20 million to $24 million
- We remain on pathway towards $300 million annual revenue in FY27


sky
GWM
DYNASTY
NRL TELSTRA PREMIERSHIP
maxiglass
Best Foods

APPENDIX

Appendix 1: History of AFT Pharmaceuticals

AFT was founded over 25 years ago by Dr Hartley and Marree Atkinson. Since then, AFT has remained an Atkinson-family controlled business and has grown organically into Australia and internationally

The 2015 IPO raised funds to pursue a more aggressive (and loss-making) R&D-led growth strategy. AFT has now returned to long term profitability as intended, as the company was prior to IPO and its growth and global reach is now accelerating



Appendix 2: Australasian Product Portfolio

AFT has the #1 selling product (Maxigesic) in the Australian para-ibu[1] combo pain relief. AFT's portfolio includes a combination of over 150 proprietary, branded and generic products which address the following therapeutic areas:

Pain	Maxigesic, ParaOsteo, ZoRub OA/HP, Fenpaed, Combolieve Day/Night
Eyecare	Hylo, Novatears, CromoFresh, Opti-soothe Wipes/Mask, VitAPOS
Vitamins	Ferro-liquid, FerroTab, Ferro-F, Ferro-sachets, Lipo VitC, Lipo VitD, CalciTab
Allergy	Loraclear, Histaclear, Fexaclear, Levoclear, Allersoothe, Lorapaed, Becloclear, Steroclear
Gastrointestinal	Gastrosoothe/Forte, LaxTab, Micolette, Nausicalm, DiaRelieve
Dermatology	Crystaderm, Crystasoothe, Topiderm range, Decazol, MycoNail
Hospital	Maxigesic IV, Injectables

[1] Paracetamol and Ibuprofen

Appendix 3: AFT Global Product Portfolio

AFT is building the global presence of its proprietary and patented products through its network of licensees and distributors.

It continues the development of its portfolio of repurposed medicines: Maxigesic[1], Pascomer, NasoSURF, and Crystaderm

Pain	Maxigesic oral dose forms - Tablets - Solution - Hot drink sachet - Rapid tablets - Cold and Flu - Day& Night ZoRub Osteo and HP
Hospital	Maxigesic IV (intravenous) NasoSurf – nasal nebuliser drug delivery
Dermatology	Crystaderm – selected territories
Gastroenterology	Kiwisoothe Micolette

[1] *Paracetamol and Ibuprofen*

Appendix 4: Reconciliation of EBITDA to GAAP

AFTs standard profit measure prepared under New Zealand GAAP is net profit after tax. AFT has used the non-GAAP profit measure of EBITDA when discussing financial performance in this document. AFT directors and management believe that this measure provides useful information as it is used internally to evaluate performance of business units, to establish operational goals and to allocate resources.

Non-GAAP profit measures are not prepared in accordance with NZ IFRS (New Zealand International Financial Reporting Standards) and are not uniformly defined, therefore the non-GAAP profit measures reported in this document may not be comparable with those that other companies report and should not be viewed in isolation or considered as a substitute for measures reported by AFT in accordance with NZ IFRS.

Six months to 30 September	2025 $000	2024 $000
Net profit after tax	**2,724**	**2,456**
Less: Finance income	(5)	(22)
Add back: Interest costs	1,230	1,357
Add back other finance loss/(gain)	(925)	(299)
Add back: Depreciation	538	490
Add back: Amortisation	1,281	653
Add back: Income tax expense/(benefit)	1,713	(383)
EBITDA	**6,556**	**(660)**

FOR MORE INFORMATION

Dr Hartley Atkinson
Managing Director
Email: hartley.atkinson@aftpharm.com

Malcolm Tubby
Chief Financial Officer
Email: malcolm.tubby@aftpharm.com

AFT Pharmaceuticals Limited
Level 1, 129 Hurstmere Road
Takapuna, Auckland 0622
New Zealand
www.aftpharm.com

AFT pharmaceuticals

Working to improve your health

2026 INTERIM REPORT

Results for the half year to 30 September 2025

AFT pharmaceuticals

Working to improve your health

Contents

This report provides a summary review of AFT's operational and financial performance for the six months to 30 September 2025 and should be read in conjunction with the company's financial statements on pages 16 to 32 of this report.

The information provided in this report has been compiled in accordance with relevant law, rules and corporate governance recommendations for investor reporting. Financial information has been prepared in accordance with appropriate accounting standards and has been reviewed by Deloitte Limited.

Throughout this report we have focused on what we believe matters most to our stakeholders and our business. We have endeavoured to ensure all information is accurate through internal verification and other approval processes.

David Flacks
Chair

Dr Hartley Atkinson
Managing Director

AFT Pharmaceuticals has reported a strong first-half performance for the six months to 30 September 2025, demonstrating continued execution against our strategy and the impact of a return to normalised trading conditions in Asia and in our international business.

We have seen solid performance across all regions. We continue to make good progress advancing the development of our International business hubs and we have advanced our research and development portfolio, and our active out and in-licensing programs. We continue to position the company for long term growth and value creation.

10 years of consecutive first half year revenue growth since listing

$114.9m

Half-year operating revenue rises 33% led by growth in Australia and a recovery from the 1H 25 trading disruptions in Asian and International markets.

$4.7m

Operating profit up from prior period losses and with ongoing investment in International business hubs and research and development

$2.7m

Net profit after tax improves from $2.5 million loss in 1H 25

OUR STRATEGIC ACHIEVEMENTS

On track to deliver $300 million
group revenue in FY 27

International business development advances
with the UK and South Africa business hubs set to contribute to earnings in 2H 26

Active licensing programme continues
with our novel iron infusion product now in development out licensed to China's Grand Life Sciences Group

Research and development programme advances with
IND applications lodged
for our antibiotic eyedrop and strawberry birthmark projects

Preparing a
Maxigesic IV study
for paediatric populations

AUSTRALIA

Revenue:
$66.5 million
up 31%
from $50.8 million.

Operating profit
$9.6 million
up from $4.0 million.

Key growth drivers:
Broad growth across categories.

NEW ZEALAND

Revenue:
$28.0 million
up 8%
from $26.0 million.

Operating profit
$4.1 million
up from $3.7 million.

Key growth drivers:
Broad growth across categories.

ASIA

Revenue:
$7.5 million
up 69%
from $4.4 million.

Operating profit
$2.1 million
up from $0.5 million.

Key drivers:
A rebound from disruptions in 1H 25 in South Korea and sales growth in other Asian markets.

INTERNATIONAL

Revenue:
$12.9 million
up 133%
from $5.6 million.

Operating loss
$(4.4) million loss
from $(4.6) million

Key drivers:
A recovery from destocking in 1H 25 and increased licensing income.

Increasing the diversity of our revenue

1H26 Revenue



1H25 Revenue



Consistent revenue growth

AFT Pharmaceuticals Revenue



Delivering against strategy

Dear Shareholders,

AFT Pharmaceuticals has reported a strong first-half performance for the six months to 30 September 2025. It is a result that demonstrates continued execution against our strategy and the impact of a return to normalised trading conditions in Asia and in our international business.

We have seen solid performance across all regions with results being particularly pleasing in our largest market, Australia. We continue to make good progress advancing the development of our international business hubs in markets that share similar characteristics with our highly successful Australasian operations.

We expect our business hubs in the United Kingdom and South Africa to begin to contribute to earnings in the second half of the year, validating the potential we see in these markets and our investment in them.

We have also advanced the company's research and development (R&D) portfolio, and our active out and in-licensing programs which continue to position the company for long term growth.

FINANCIAL PERFORMANCE

Revenue grew by 33% to $114.9 million from $86.7 million in 1H 25 – the 10th consecutive period of first half-year revenue increasing against the same period of the prior year since listing on the NZX. Growth was driven by the Australian business, up 31% to $66.5 million with solid performances across key OTC and pharmacy brands and continued uptake in prescription medicines.

It was also supported by an improving contribution from the International business (up 133% to $12.9 million) and Asia (up 69% to $7.5 million) as the one-off factors that affected 1H25 trading – a doctors' strike in Korea and international customer de-stocking – were resolved in 2H 25.

Gross margin was 43.2%, reflecting a small increase in margin from product sales and royalties and $1.8 million additional license income on commercial sales.

Operating expenses increased 18% as the company continued to fund growth initiatives from its own resources, including: (i) start-up and scaling costs for the business hubs in North America, the UK/ Europe and South Africa; (ii) brand and market entry investments to support recent and upcoming launches; and (iii) higher R&D expenses to advance late-stage projects.

The resulting operating profit was $4.7 million, up $6.5 million from a $1.8 million loss in 1H 25. EBITDA was $6.6 million, up $7.3 million from a $0.7 million loss in 1H 25. Net profit after tax was $2.7 million from a $2.5 million loss in 1H 25.

Revenue by region



AFT remains on track to deliver a FY26 operating profit within the previously outlined range.

RESEARCH AND DEVELOPMENT

R&D expenditure (expensed and capitalised) in the half year was $9.5 million up from $8.9 million in 1H 25 as we advanced a diversified portfolio of development projects spanning pain, dermatology and eyecare.

We made notable progress across several late-stage programmes:

- Intravenous iron: Following the positive Phase III trial, AFT and its development partners are now preparing to commence a large global Phase III confirmatory study of ~1,000 patients. Two additional patent applications have been filed to further protect the asset.
- Antibiotic eyedrop: The pre-IND application[1] has been filed with the US FDA, with IND submission targeted early next financial year to enable first-in-human studies. The product seeks to address drug-resistant ocular infections for which registered therapies are limited. Current treatments are primarily prepared by compounding pharmacies which is not desirable, especially for eyecare products where full GMP sterility is a crucial factor.
- Topical strawberry birthmarks: The pre-IND has been prepared and filed; FDA feedback has been received which guides the IND submission pathway and Phase I, II and III study designs.
- Maxigesic IV paediatric: We are preparing to commence a Maxigesic IV study for paediatric populations, following FDA approval of our paediatric study plan. Our medicine offers a new option for pain care in children, who have fewer safe and effective options for managing pain compared to adults, particularly in hospital settings.

We have progressed out-licensing discussions — securing five agreements in the 1H 26 period. A key achievement has been the out-licensing agreement for our novel IV iron therapy for China[2] which was secured after the 1H 26 period.

The agreement, with Chengdu-based Grand Life Sciences Group, a top five Chinese pharmaceutical company by sales revenue, features upfront, development and sales milestone payments as well as recurring royalties. This revenue will be shared between AFT and its development partners. Grand Life Sciences will also contribute to funding the global clinical development program.

We also advanced our in-licensing programme to deepen our product portfolio. A number of products in-licensed are now either in registration or are being prepared for regulatory filing. In many cases we have secured in-licensing across multiple territories to include the new AFT business hubs, further advancing the leverage we gain from these activities.

Collectively, the R&D and business development programmes will support multiple launches over the next several years, broadening our product portfolio and increasing both the size and the diversity of revenue through direct sales and through licensing and royalty income.

INTERNATIONAL DEVELOPMENT

AFT continues to direct significant effort towards the development of sales in the international business hubs, which share the characteristics of our highly successful Australasian operations.

"We are pleased with the progress we are making in the United Kingdom and expect operations to reach breakeven in the second half of this current financial year."

We continue to focus upon growing the Combogesic tablets and IV brands. A recent success has been the addition of Combogesic to the formulary of London Northwest University Healthcare NHS Trust. This trust covers Ealing Hospital and the Northwick Park Hospital, which hosts the UK's largest and busiest Accident and Emergency Department. A significant number of regulatory filings are underway for both AFT proprietary products and new products we have in-licensed to the UK, supporting a strong product launch pipeline.

[1] IND: Investigational New Drug application.

[2] Licensing negotiations enabled by Ms Hong Xie, Pharma China Consulting.

In Canada we launched our first product, Combogesic IV in 1H 26 and we are planning additional launches in 2H 26. Our team, led by experienced Canadian pharma executive, Sylvain Desjeans, is now fully operational. We continue to work on a significant number of regulatory filings in the 2H 26 time period in order to further expand our product portfolio in Canada.

We accelerated our product launch schedule in South Africa from four to eighteen products in this financial year and we have agreed to acquire some additional product licenses. This will significantly accelerate sales growth in the new financial year. The business is expected to contribute to group earnings in 2H 26. Our South African team is in place, led by experienced South African pharma executive, Deon Hall.

BALANCE SHEET

AFT remains well funded, with net debt of $20.9 million[3] at 30 September 2025 ($18.9 million, 30 September 2024), within our target leverage range and reflecting continued investment in growth. Discussions on renewal of the banking facility are well advanced. Inventory was $58 million, managed prudently against normalising supply chains and the anticipated launches in the second half.

OUTLOOK

Consistent with prior years, AFT expects second half sales and earnings to be greater than the first half of FY26 supported by a strong programme of launches in International markets, continued expansion in the Australasian portfolio, and increasing contributions from the company's international business hubs as they scale.

AFT remains focused on disciplined execution: converting R&D progress into value through clinical and regulatory milestones; advancing out-licensing to monetise our IP; and deepening in-licensing to add attractive, strategically aligned products in priority markets.

Our R&D and international expansion efforts come at the expense of short-term earnings, but they will support the extension of AFT's decades-long record of delivering uninterrupted growth and shareholder value creation. They will also deliver the product and geographic diversification that underpins the resilience of the business.

AFT remains on track to deliver a FY26 operating profit within the previously outlined range of $20 million to $24 million. The company also reiterates its confidence in its pathway to $300 million annual revenue in FY27, supported by the launch schedule, our licensing programme, the scaling of international hubs and continued geographic expansion.

With our warm regards,

David Flacks
Chair

Dr Hartley Atkinson
Managing Director

[3] Exclusive of related party loan

Extending our reach diversifying our earnings

AUSTRALIA

Revenue:
$66.5m
up 31% from $50.8 million

Operating profit
$9.6m
up from $4.0 million

Revenue in Australia grew 31% to $66.5 million from $50.8 million in 1H 25. Revenue was lifted by strong growth in all channels.

Growth was led by eyecare, pain relief, iron supplements and the company's broad portfolio of injectables.

The existing products led this growth and product launches over the last year and the planned pipeline of products will contribute as they become established in the market. Australian operating profit was $9.6 million up from the $4.0 million in 1H 26 consistent with the ongoing operating leverage achieved after the investment in sales and marketing spend.

NEW ZEALAND

Revenue:
$28.0m
up 8% from $26.0 million

Operating profit
$4.1m
up from $3.7 million.

Revenue in New Zealand grew 8%, in line with planned growth, to $28.0 million from $26.0 million in 1H 25. Revenue growth was led by allergy, dermatology and eyecare.

New Zealand operating profit improved to $4.1 million from $3.7 million in 1H 25, driven by the revenue growth. Although growth was less than other divisions, ongoing growth is targeted in the New Zealand market.



ASIA

Revenue:
$7.5m
up 69% from $4.4 million

Operating profit
$2.1m
up from $0.5 million.

Asian revenue was $7.5 million up from $4.4 million in 1H 25. The strong uplift was driven by the rebound in sales in South Korea, where a doctors' strike suppressed sales in 1H 25 and growing sales in other Asian markets.

We continue to focus upon growing and diversifying sales within the Asia region, which offers significant potential upside.

Operating profit was $2.1 million, up from $0.5 million in 1H 25 reflecting the increase in sales.

INTERNATIONAL

Revenue:
$12.9m
up 133% from $5.6 million

Operating profit
$(4.4)m
loss, from $(4.6) million

Revenue from product sales and royalties in the international business was $11.0 million up 104% from $5.4 million in 1H 25. The improvement in performance was driven by a return to more normal patterns in trading after customer de-stocking in 1H 25 weighed on that period's financial performance. Licensing income of $1.9 million was $1.8 million up on the $0.2 million of 1H 25.

Including licensing income, we recorded an operating loss of $4.4 million compared to a loss of $4.6 million in 1H 25. The result was supported by an increase in gross profit from sales and royalties and followed increased investment in research and development and ongoing investment to establish our business hubs in North America, the UK, Europe and South Africa (see next page).

Building revenue momentum in new markets

AFT has made good progress advancing its strategy to develop business hubs in markets that offer similar trading characteristics as its successful Australasian business, the current engine of the company's growth. We are seeing early evidence of the promise these offer to the company. Notably our operations in the United Kingdom and South Africa are expected to make a contribution to the group result in the second half of the year.

AFT Pharmaceuticals UK

In the UK we have expanded the reach and uptake of our Maxigesic products, marketed locally as Combogesic, and the business is on track to contribute to the group results in the second half of this financial year.

We have extended our distribution of Combogesic tablets to 2,500 Boots and SuperDrug stores as well as online via Amazon and now independent pharmacies across the country.

The initial rollouts of Combogesic IV in several London NHS hospitals are now well established, with the product beginning to gain traction through new formulary listings. Notably, the medicine has been included in the formulary of London Northwest University Healthcare NHS Trust. This covers both Ealing Hospital and Northwick Park Hospital, the UK's largest and busiest Accident and Emergency Department. AFT sees progress with the NHS as an important precursor to significantly expanding distribution and sales across the UK for Combogesic IV.

We continue to focus on expanding our product offerings in the UK market with new regulatory filings.

AFT Pharmaceuticals South Africa

In South Africa we have accelerated our product launch program, growing the planned number of launches in 2H 26 from the planned 4 to now 18. The company now has a robust pipeline planned for introduction into the private hospital market. We have appointed Deon Hall, an executive with deep experience in the hospital sector, as CEO to help drive the planned expansion.

AFT Pharmaceuticals North America

In Canada we have recently launched Combogesic IV. Several additional launches are planned over the next year with the first being the launch of Combogesic tablets, which we have taken over from the current Canadian distributor.

We have a strong Canadian pipeline either already filed with Health Canada for registration or in the process of dossier preparation for regulatory filing.

This diversified portfolio includes AFT's own intellectual property, in-licensed products, and formulations in collaboration with AFT Pharm Sinoject. Canada is around eighteen to twenty-four months behind the UK in terms of business development, but we believe that it is an attractive market once we become established.

In the US our focus is on Combogesic IV and a range of over-the-counter medicines. In late May we extended our license with Hikma Pharmaceuticals to cover both the intravenous and tablet (Combogesic Rapid) forms. The new agreement is aimed to maximize the commercial and patient care benefits that come with following the intravenous form of the pain relief medicine in postoperative care with the tablets.

Other Markets

We meanwhile continue to work closely with partners in Europe and our own operations in Hong Kong and Singapore to advance these significant potential markets as well as additional new launches.

Maximising the value of our IP and extending our portfolio

Our active licensing programme continues to deliver value – offering opportunities to generate revenue from markets where we have no direct presence and extending the portfolio in regions where we do.

During 1H 26 we made five out-licensing agreements. We expect deal momentum to continue for the remainder of the year with discussions continuing for a number of our medicines.

Just after the end of the half year period we out-licensed our novel IV iron therapy for China[4] with the Chengdu-based Grand Life Sciences Group. The agreement features upfront, development and sales milestone payments as well as recurring royalties. These will be shared between AFT and its development partners. Additionally, Grand Life Sciences will contribute to funding the global clinical development program.

In addition to discussions covering our Maxigesic family of medicines for some remaining territories, we are in multiple discussions to out license other medicines that have recently emerged from our development programme including Crystaderm, Capsaicin pain relieving cream, Kiwisoothe tablets and sachets, and our Micolette micro enema. The portfolio of injectables we are developing in our AFT Sinoject partnership are also attracting interest.

For our novel injectable iron product, AFT and Hyloris, continue to receive significant unsolicited interest but presently our plan is to restrict early phase licensing to countries where a local partner is essential for development and to maximise value by advancing the development program.

We also maintain an active in-licensing programme to grow our product portfolio largely to satisfy unmet clinical needs. An example is a ready-to-use tranexamic acid mouthwash (a medicine to help reduce or prevent excessive bleeding) which would enable patients treated with anticoagulants undergoing oral surgery to avoid the current necessity to discontinue their anticoagulant medications before oral surgery. We also continue to explore the purchase of products in some markets to further accelerate growth.

[4] Licensing negotiations enabled by Ms Hong Xie, Pharma China Consulting

Reconciliation of EBITDA to GAAP

AFT's standard profit measure prepared under New Zealand GAAP is net profit after tax. AFT has used the non-GAAP profit measure of EBITDA when discussing financial performance in this document. AFT directors and management believe that this measure provides useful information as it is used internally to evaluate performance of business units, to establish operational goals and to allocate resources. Non-GAAP profit measures are not prepared in accordance with NZ IFRS (New Zealand International Financial Reporting Standards) and are not uniformly defined, therefore the non-GAAP profit measures reported in this document may not be comparable with those that other companies report and should not be viewed in isolation or considered as a substitute for measures reported by AFT in accordance with NZ IFRS.

GAAP to Non-GAAP reconciliation		
NZ$'000's **Six months to the end September**	**2025**	**2024**
Net Profit after tax	2,724	(2,456)
Less: Finance income	(5)	(22)
Add back: Interest costs	1,230	1,357
Add back: Other finance loss/(gain)	(925)	(299)
Add back: Depreciation	538	490
Add back: Amortisation	1,281	653
Add back: Income tax expense/(benefit)	1,713	(383)
EBITDA	**6,556**	**(660)**

AFT Pharmaceuticals Limited

CONSOLIDATED FINANCIAL STATEMENTS

Results for the half year to 30 September 2025

Deloitte.

Independent Auditor's Report

To The Shareholders Of AFT Pharmaceuticals Limited

Conclusion

We have reviewed the condensed consolidated interim financial statements ('interim financial statements') of AFT Pharmaceuticals Limited ('the Company') and its subsidiaries ('the Group') on pages 16 to 32 which comprise the consolidated balance sheet as at 30 September 2025, consolidated income statement and the consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the six months ended on that date, and notes to the interim financial statements, including material accounting policy information.

Based on our review, nothing has come to our attention that causes us to believe that the interim financial statements of the Group do not present fairly, in all material respects, the financial position of the Group as at 30 September 2025 and its financial performance and cash flows for the six months ended on that date in accordance with *NZ IAS 34 Interim Financial Reporting* and *IAS 34 Interim Financial Reporting*.

Basis for Conclusion

We conducted our review in accordance with NZ SRE 2410 (Revised) *Review of Financial Statements Performed by the Independent Auditor of the Entity* ('NZ SRE 2410 (Revised)'). Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Interim Financial Statements* section of our report.

We are independent of the Group in accordance with the relevant ethical requirements in New Zealand relating to the audit of the annual financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Other than in our capacity as auditor, we have no relationship with or interests in AFT Pharmaceuticals Limited or its subsidiaries.

Directors' responsibilities for the interim financial statements

The directors are responsible on behalf of the Company for the preparation and fair presentation of the interim financial statements in accordance with NZ IAS 34 *Interim Financial Reporting* and *IAS 34 Interim Financial Reporting* and for such internal control as the directors determine is necessary to enable the preparation and fair presentation of the interim financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibilities for the review of the interim financial statements

Our responsibility is to express a conclusion on the interim financial statements based on our review. NZ SRE 2410 (Revised) requires us to conclude whether anything has come to our attention that causes us to believe that the interim financial statements, taken as a whole, are not prepared, in all material respects, in accordance with NZ IAS 34 *Interim Financial Reporting* and IAS 34 *Interim Financial Reporting*.

A review of the interim financial statements in accordance with NZ SRE 2410 (Revised) is a limited assurance engagement. We perform procedures, primarily consisting of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with International Standards on Auditing (New Zealand) and consequently do not enable us to obtain assurance that we might identify in an audit. Accordingly we do not express an audit opinion on the interim financial statements.

Restriction on use

This report is made solely to the Company's shareholders, as a body. Our review has been undertaken so that we might state to the Company's shareholders those matters we are required to state to them in a review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company's shareholders as a body, for our engagement, for this report, or for the conclusions we have formed.

Bryce Henderson, Partner
for Deloitte Limited
Auckland, New Zealand
20 November 2025

Consolidated Income Statement

For the Six Months Ended 30 September 2025

	Note	Unaudited 6 Months Ended 30 Sep 2025 $'000	Unaudited 6 Months Ended 30 Sep 2024 $'000
Revenue	4	114,942	86,713
Cost of sales		(65,252)	(50,514)
Gross profit		**49,690**	**36,199**
Other (expense)/income		(636)	-
Selling and distribution expenses		(30,202)	(26,695)
General and administrative expenses		(8,001)	(6,008)
Research and development expenses		(6,114)	(5,299)
Operating profit/(loss)		**4,737**	**(1,803)**
Finance income		5	22
Interest costs		(1,230)	(1,357)
Other finance gain / (loss)		925	299
Profit/(loss) before tax		**4,437**	**(2,839)**
Income tax (expense)/benefit		(1,713)	383
Profit/(loss) after tax		**2,724**	**(2,456)**
Profit/(loss) is attributable to:			
Equity holder of the parent		3,298	(2,186)
Non-controlling interests		(574)	(270)
Earnings per share			
Basic and diluted earnings per share ($)		$0.03	($0.02)

The accompanying Notes form an integral part of the consolidated Financial Statements.

Consolidated Statement Of Comprehensive Income

For the Six Months Ended 30 September 2025

	Note	Unaudited 6 Months Ended 30 Sep 2025 $'000	Unaudited 6 Months Ended 30 Sep 2024 $'000
Profit/(loss) after tax		**2,724**	**(2,456)**
Other comprehensive income			
Items that may be subsequently reclassified to profit and loss:			
Foreign exchange difference on translation of foreign operations		64	(188)
Other comprehensive income/(loss) for the year, net of tax			
Total comprehensive income/(loss)		**2,788**	**(2,644)**
Total comprehensive income is attributable to:			
Equity holder of the parent		3,362	(2,374)
Non-controlling interests		(574)	(270)
		2,788	**(2,644)**

The accompanying Notes form an integral part of the consolidated Financial Statements.

Consolidated Statement Of Changes In Equity

For the Six Months Ended 30 September 2025

	Note	Share capital	Share options reserve	Foreign currency translation reserve	Retained earnings	Total	Non-controlling interests	Total
		$'000	$'000	$'000	$'000	$'000	$'000	$'000
Balance 31 March 2024		**78,240**	**139**	**159**	**9,257**	**87,795**	**-**	**87,795**
Unaudited								
Six months to 30 September 2024								
Loss after tax		-	-	-	(2,186)	(2,186)	(270)	(2,456)
Other comprehensive income		-	-	(188)	-	(188)	-	(188)
Total comprehensive income		**-**	**-**	**(188)**	**(2,186)**	**(2,374)**	**(270)**	**(2,644)**
Movement in share options reserve		-	56	-	-	56	-	56
Dividends paid		-	-	-	(1,678)	(1,678)	-	(1,678)
Balance 30 September 2024		**78,240**	**195**	**(29)**	**5,393**	**83,799**	**(270)**	**83,529**
Audited								
Year ended 31 March 2025								
Profit after tax		-	-	-	11,962	11,962	(562)	11,400
Other comprehensive income		-	-	(342)	-	(342)	-	(342)
Total comprehensive income		-	-	**(342)**	**11,962**	**11,620**	**(562)**	**11,058**
Movement in share options reserve		-	41	-	-	41	-	41
Transfer to retained earnings		-	(139)	-	-	(139)	-	(139)
Dividends paid		-	-	-	(1,678)	(1,678)	-	(1,678)
Balance 31 March 2025		**78,240**	**41**	**(183)**	**19,541**	**97,639**	**(562)**	**97,077**
Six months to 30 September 2025								
Profit after tax		-	-	-	3,298	3,298	(574)	2,724
Other comprehensive income		-	-	64	-	64	-	64
Total comprehensive income		**-**	**-**	**64**	**3,298**	**3,362**	**(574)**	**2,788**
Movement in share options reserve		-	10	-	-	10	-	10
Dividends paid		-	-	-	(1,888)	(1,888)	-	(1,888)
Balance 30 September 2025		**78,240**	**51**	**(119)**	**20,951**	**99,123**	**(1,136)**	**97,987**

The accompanying Notes form an integral part of the condensed consolidated interim Financial Statements.

Consolidated Balance Sheet

As at 30 September 2025

	Note	Unaudited 30 Sep 2025 $'000	Audited 31 Mar 2025 $'000	Unaudited 30 Sep 2024 $'000
ASSETS				
Current assets				
Inventories		57,842	48,476	47,874
Trade and other receivables		36,948	48,564	28,000
Cash and cash equivalents		12,099	11,110	10,686
Derivative assets	12	92	192	216
Total current assets		**106,981**	**108,342**	**86,776**
Non-current assets				
Property, plant and equipment		425	479	440
Intangible assets		60,373	58,223	56,500
Right of use assets		3,171	2,771	3,059
Deferred tax		672	-	1,118
Total non-current assets		**64,641**	**61,473**	**61,117**
Total assets		**171,622**	**169,815**	**147,893**
LIABILITIES				
Current liabilities				
Trade and other payables		27,682	33,105	25,280
Provisions		6,088	5,665	4,192
Lease liabilities	7	854	728	752
Current income tax liability		1,995	2,675	1,058
Derivative liabilities	12	-	-	195
Related party loan	7	1,158	1,083	439
Interest bearing liabilities	7	32,987	-	-
Total current liabilities		**70,764**	**43,256**	**31,916**
Non-current liabilities				
Lease liabilities	7	2,871	2,586	2,848
Interest bearing liabilities	7	-	25,600	29,600
Deferred tax		-	1,296	-
Total non-current liabilities		**2,871**	**29,482**	**32,448**
Total liabilities		**73,635**	**72,738**	**64,364**
EQUITY				
Share capital	8	78,240	78,240	78,240
Retained earnings/(losses)		20,951	19,541	5,393
Share options reserve		51	41	195
Foreign currency translation reserve		(119)	(183)	(29)
Equity attributable to equity holder of the parent		**99,123**	**97,639**	**83,799**
Non-Controlling Interests		(1,136)	(562)	(270)
Total equity		**97,987**	**97,077**	**83,529**
Total liabilities and equity		**171,622**	**169,815**	**147,893**

The accompanying Notes form an integral part of the condensed consolidated interim Financial Statements.

On behalf of the Board on 20th November 2025

David Flacks
Chair

Dr Hartley Atkinson
Founder and Chief Executive Officer

Consolidated Statement Of Cash Flows

For the Six Months Ended 30 September 2025

	Unaudited 6 Months Ended 30 Sep 2025 $'000	Unaudited 6 Months Ended 30 Sep 2024 $'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Receipts from customers	125,966	103,666
Payments to suppliers and employees	(121,129)	(98,084)
Tax paid	(4,361)	(1,229)
Net cash generated from operating activities	**476**	**4,353**
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of property, plant and equipment	(64)	(150)
Purchase of intangible assets	(3,431)	(3,789)
Net cash used in investing activities	**(3,495)**	**(3,939)**
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issue of share capital	-	-
Dividends paid	(1,887)	(1,678)
Payment for lease liabilities per lease schedule	(410)	(408)
Borrowings drawn	6,500	1,400
Related party loan	75	439
Interest received	5	22
Interest paid on lease liabilities	(135)	(146)
Interest costs paid on borrowings	(1,095)	(1,211)
Net cash used in financing activities	**3,053**	**(1,582)**
Net decrease in cash	34	(1,168)
Impact of foreign exchange on cash and cash equivalents	68	(186)
Opening cash and cash equivalents	11,110	12,040
Closing cash and cash equivalents	**11,212**	**10,686**
Made up of:		
Cash and cash equivalents	12,099	10,686
BNZ overdraft	(887)	-
	11,212	**10,686**

The accompanying Notes form an integral part of the consolidated Financial Statements.

Reconciliation Of Profit After Tax With Net Cash Flow From Operating Activities

	30 Sep 2025 $'000	30 Sep 2024 $'000
Profit/(Loss) after tax	**2,724**	**(2,456)**
Non-cash items and items classified as financing activities		
Depreciation	117	73
Depreciation ROU assets	421	417
Amortisation	1,281	653
Intangible disposals	-	96
Share options expense	10	56
Interest on lease liabilities	135	146
Interest and finance expense	1,095	1,211
Unrealised (gain)/loss on foreign currency movements	96	385
Provision for tax expense	(2,648)	(1,612)
Interest received	(5)	(22)
Movement in working capital		
Decrease/(increase) in inventories	(9,366)	1,183
Decrease/(increase) in trade and other receivables	11,616	16,222
(Decrease)/increase in trade and other payables, provisions	(5,000)	(11,999)
Net cash generated from operating activities	**476**	**4,353**

The accompanying Notes form an integral part of the consolidated Financial Statements.

Notes To The Financial Statements

For the six months ended 30 September 2025

1. Reporting Entity

AFT Pharmaceuticals Ltd (the "Company" or "Parent") together with its subsidiaries (the "Group") is a pharmaceutical distributor and developer of pharmaceutical intellectual property. The Company is incorporated and domiciled in New Zealand; it is registered under the Companies Act 1993. The address of the Company's registered office is 129 Hurstmere Road, Takapuna, New Zealand.

The Company is an FMC reporting entity under the Financial Markets Conduct Act 2013 and is listed on both the NZX and ASX.

These condensed consolidated interim financial statements were approved by the Directors on 20th November 2025 and are not audited but have been reviewed by Deloitte Limited in accordance with NZ SRE 2410 (Revised) Review of Financial Statements Performed by the Independent Auditor of the Entity.

2. Basis of Preparation And Principles Of Consolidation

Statement of compliance

These general-purpose financial statements for the six months to 30 September 2025 have been prepared in accordance with New Zealand Generally Accepted Accounting Practice (NZ GAAP). They comply with NZ IAS 34 and IAS 34, Interim Financial Reporting. The Group is a for-profit entity for the purposes of complying with NZ GAAP.

The condensed consolidated interim financial statements do not include all the notes normally included in an annual financial report. Accordingly, this report should be read in conjunction with the audited financial statements for the year ended 31 March 2025, which have been prepared in accordance with the New Zealand equivalents to IFRS Accounting Standards ('NZ IFRS') and IFRS Accounting Standards ('IFRS').

The same accounting policies and methods of computation are followed in the condensed consolidated interim financial statements as compared to the audited financial statements for the year ended 31 March 2025, as described in those annual financial statements.

Basis of accounting

These consolidated financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and liabilities (including derivative instruments) at fair value through profit or loss and/or other comprehensive income.

Functional and presentation currency

The consolidated financial statements are presented in New Zealand dollars (NZD), which is the Company's functional currency rounded to the nearest thousand dollars unless otherwise stated. Items included in the financial statements of each of the subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the functional currency).

Foreign currency transactions and balances

The results and balance sheets of all foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from New Zealand dollars are translated into the presentation currency as follows:

- Monetary assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet.
- Income and expenses for each income statement and statement of comprehensive income are translated at average exchange rates, unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions.
- Exchange differences arising are recognised in other comprehensive income and accumulated in a foreign exchange translation reserve.
- Non-monetary items carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Basis of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of the Group as at the balance date and the results of all subsidiaries for the six-month period then ended.

Intercompany transactions, balances and unrealised gains on transactions between subsidiary companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred.

Critical accounting estimates and judgements

In applying the Group's accounting policies, the directors are required to make judgements (other than those involving estimations) that have a significant impact on the amounts recognised and to make estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

Significant estimates are disclosed in each of the applicable notes to the financial statements and are designated with an E symbol.

Material accounting policy information

Material accounting policies are disclosed in each of the applicable notes to the financial statements and are designated with an AP symbol. All mandatory amendments have been adopted in the current year. None had a material impact on these financial statements. The accounting policies applied by the Group in the preparation of the condensed consolidated interim financial statements are the same as those applied by the Group in the preparation of its consolidated financial report for the year ended 31 March 2025. The accounting policies have been applied consistently throughout the Group for the purposes of this interim report.

Standards and interpretations in issue not yet effective

At the date of authorisation of these financial statements, the Group has not applied new and revised NZ IFRS standards and amendments that have been issued but are not yet effective. It is not expected that the adoption of these standards and amendments will have a material impact on the financial statements of the Group.

In April 2024, the International Accounting Standards Board introduced IFRS 18 Presentation and Disclosure in Financial Statements (effective for reporting periods beginning on or after 1 January 2027). This standard replaces IAS 1 Presentation of Financial Statements. An equivalent, NZ IFRS 18 was issued on 23 May 2024. NZ IFRS 18 also applies to reporting periods (including interim periods) beginning on or after 1 January 2027 and will replace NZ IAS 1. Management are still assessing the impact and note this may change the presentation of primary statements.

Goods and Services Tax (GST)

The income statement and the statement of comprehensive income have been prepared so that all components are stated exclusive of GST. All items in the balance sheet are stated net of GST, with the exception of accounts receivable and payable, which include GST invoiced. All components of the statement of cash flows are stated exclusive of GST.

3. Significant Transactions And Events In The Financial Year

There were no significant transactions or events in the six months to 30th September 2025.

4. Revenue From Operations

	Unaudited 6 Months Ended 30 Sep 2025 $'000	Unaudited 6 Months Ended 30 Sep 2024 $'000
Sale of goods	111,577	85,595
Royalty income	1,427	950
Licensing Income	1,938	168
Total revenue from operations	**114,942**	**86,713**

AP E

Revenue is measured based on the consideration to which the Group expects to be entitled in a contract with a customer and excludes amounts collected on behalf of third parties:

- The sale of goods, excluding GST and discounts are recognised when control of the product is transferred to the customer at a point in time. For discounts not invoiced at reporting date, these are estimated based on agreements with customer and estimated depletions during the period.
- Licensing income, the Group has entered into a number of out-licencing contracts whereby the Group's obligations are the provision of territorial rights to the company's intellectual property and the provision and support of the documentation required to enable registration of the product in the territory. The Group typically receives an upfront fee, milestone payments for specific registration and/or development-based outcomes, and sales-based milestones or royalties as consideration for the license.

  Licenses coupled with other services, must be assessed to determine if the license is distinct (that is, the customer must be able to benefit from the IP on its own or together with other resources that are readily available to the customer, and the Group's promise to transfer the IP must be separately identifiable from other promises in the contract). If the license is not distinct, then the license is combined with other goods or services into a single performance obligation. Revenue is then recognised as the Group satisfies the combined performance obligation.

A license will either provide:

- A right to access the entity's intellectual property throughout the license period, which results in revenue that is recognised over time;

or

- A right to use the entity's intellectual property as it exists at the point in time in which the license is granted, which results in revenue that is recognised at a point in time. For sales or usage-based royalties that are attributable to a license of IP, the amount is recognised at the later of:
  - when the subsequent sale or usage occurs; and
  - the satisfaction or partial satisfaction of the performance obligation to which some or all of the sales or usage-based royalty has been allocated.
- Royalty revenue is recognised on an actual and accrual basis in accordance with the substance of the relevant agreement provided that it is probable that economic benefits will flow to the Company and the amount of revenue can be measured reliably.

5. Joint Operations

Hyloris Pharmaceuticals SA and AFT have been collaborating in the development of the Maxigesic IV product. AFT has now licensed the product to a number of partners covering multiple countries. Maxigesic IV is protected by several granted and pending patent applications. Under the terms of the development collaboration agreement between Hyloris and AFT, Hyloris is eligible to receive a share on any product related revenues, such as license fees, royalties, milestone payments, received by AFT. The arrangement constitutes a joint operation whereby the Group recognises, in relation to its interest in the joint operation, its share of assets and liabilities in the consolidated statement of financial position and share of revenue earned and expenses incurred in the consolidated income statement. The Group accounts for the assets, liabilities, revenues and expenses relating to its interest in the joint operation in accordance with the NZ IFRS standards applicable to the particular assets, liabilities, revenues and expenses.

AP

Interests in joint operations

A joint operation is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require unanimous consent of the parties sharing control.

6. Segment Reporting

	Operating Segments					
	Australia $'000	New Zealand $'000	Asia $'000	Rest of World $'000	Head Office $'000	Total $'000
Unaudited 6 months to 30 September 2025						
Revenue - Sale of goods	66,483	28,026	6,716	10,352	-	111,577
Revenue - Royalties	-	-	793	634	-	1,427
Revenue - Licensing	-	-	-	1,938	-	1,938
Total revenue	**66,483**	**28,026**	**7,509**	**12,924**	**-**	**114,942**
Other (expense)/ income	-	-	-	(636)	-	(636)
Depreciation - ROU assets	259	31	-	-	131	421
Depreciation - Other	16	-	-	-	101	117
Amortisation	-	-	-	1,281	-	1,281
Operating profit / (loss)	**9,568**	**4,113**	**2,097**	**(4,374)**	**(6,667)**	**4,737**
Finance income	-	-	-	-	5	5
Interest expense - Loans	-	-	-	-	(1,095)	(1,095)
Interest expense - Lease liabilities	(50)	(5)	-	-	(80)	(135)
Other finance gains/(losses)	-	-	-	-	925	925
Profit / (loss) before tax	**9,518**	**4,108**	**2,097**	**(4,374)**	**(6,912)**	**4,437**
Total assets	**59,482**	**43,812**	**4**	**67,655**	**669**	**171,622**
ROU assets	1,375	111	-	-	1,685	3,171
Property plant and equipment	147	-	-	8	270	425
Pascomer IP	-	-	-	12,500	-	12,500
Other intangible assets	-	-	-	47,873	-	47,873
Total liabilities	**11,651**	**24,770**	**-**	**2,955**	**34,259**	**73,635**
Capital expenditure	**5**	**-**	**-**	**3,440**	**50**	**3,495**

	Operating Segments					
	Australia $'000	New Zealand $'000	Asia $'000	Rest of World $'000	Head Office $'000	Total $'000
Unaudited 6 months to 30 September 2024						
Revenue - Sale of goods	50,762	25,965	4,040	4,828	-	85,595
Revenue - Royalties	-	-	395	555	-	950
Revenue - Licensing	-	-	-	168	-	168
Total revenue	**50,762**	**25,965**	**4,435**	**5,551**	**-**	**86,713**
Other (expense)/income	-	-	-	-	-	-
Depreciation - ROU assets	260	26	-	-	131	417
Depreciation - Other	7	-	-	-	66	73
Amortisation	-	-	-	653	-	653
Operating profit/(loss)	**3,978**	**3,710**	**496**	**(4,637)**	**(5,350)**	**(1,803)**
Finance income	-	-	-	-	22	22
Interest expense - Loans	-	-	-	-	(1,211)	(1,211)
Interest expense - Lease liabilities	(54)	(3)	-	-	(89)	(146)
Other finance gains/(losses)	-	-	-	-	299	299
Profit / (loss) before tax	**3,924**	**3,707**	**496**	**(4,637)**	**(6,329)**	**(2,839)**
Total assets	**51,354**	**36,571**	**4**	**58,846**	**1,118**	**147,893**
ROU assets	1,051	62	-	-	1,946	3,059
Property plant and equipment	84	-	-	2	354	440
Pascomer IP	-	-	-	12,500	-	12,500
Other intangible assets	-	-	-	44,000	-	44,000
Total liabilities	**11,210**	**20,384**	**(1)**	**700**	**32,071**	**64,364**
Capital expenditure	**67**	**-**	**-**	**3,862**	**84**	**4,013**

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker (CODM). For the purposes of NZ IFRS 8, the CODM is a group comprising the Board of Directors, together with the Chief Executive Officer, the Chief of Staff, the Chief Financial Officer and the Director of International Business Development. Management report on operating segments net of intersegment revenue so that the revenue amount reflects the end customer's reportable geography.

Intersegment transactions are eliminated for Management reporting. This has been determined on the basis that it is this group that determines the allocation of the resources to segments and assesses their performance.

The Group has four operating segments based on geographical locations reportable under NZ IFRS 8, as described below, which are the Group's strategic groupings of business units. The following summary describes the operations in each of the Group's reporting segments:

- **Australia** – Includes the sales and distribution activity relating to the Australia market.
- **New Zealand** – Includes the sales and distribution activity relating to the New Zealand market.
- **Asia** – Includes the sales and distribution activity relating to the Asian market.
- **Rest of World** – Includes the sales and distribution activity relating to other markets in which the group has a direct presence, the out-licensing of IP developments to markets in which the Group does not have a presence, and the export of products to export markets. The costs of research and development and new market development activity not specific to the other segments are expensed to this segment.

Head Office – Head Office functions include maintaining all supplier relationships, procurement of inventory, regulatory activity, governance, marketing activity and finance activity.

Major Customers – Revenues from one customer of the Australian segment (being a licensed wholesaler) represents approximately NZ$21.6.m (6 months to 30 September 2024 NZ$ 15.3m) and from one customer of the New Zealand segment (also being a licensed wholesaler) represents approximately NZ$ 13.9m (6 months to September 2024: NZ$12.7m) of the Group's revenues.

7. Interest Bearing Liabilities

	Unaudited as at 30 Sep 2025 $'000	Audited as at 31 Mar 2025 $'000	Unaudited as at 30 Sep 2024 $'000
Current lease liabilities	854	728	752
Non-current lease liabilities	2,871	2,586	2,848
Related party loan	1,158	1,083	439
BNZ overdraft	887	-	-
BNZ Term loans current portion	32,100	-	-
BNZ Term loans non-current portion	-	25,600	29,600
Total	**37,870**	**29,997**	**33,639**
Opening balance of BNZ loan	25,600	28,200	28,200
BNZ loans drawn down	6,500	-	1,400
Repayment of principal	-	(2,600)	-
Closing balance	**32,100**	**25,600**	**29,600**

The BNZ loans have a general security over the assets of the Group together with a Group guarantee.

On 30 September 2022 the BNZ facility was renewed for a further three-year term through to April 2026. The facility retains a) the $18.2 million term loan, b) the $10.0 million working capital facility, c) the $3.0 million overdraft and d) the $5.0 million Business Finance Scheme Loan (BFS). The maturity date for the BFS is May 2026.

Interest on the term loan and working capital facility is the BNZ CCAF or CARL plus a margin of 1.45%. Interest on the overdraft is the BNZ market connect base rate plus a margin of 1.00%. Interest on the BFS is fixed at 2.30%. The non fixed interest rates are reset on a quarterly basis. The Group is well advanced in its discussions with local commercial banks to renew the long-term facility and has received indicative term sheets. The Group expects to have a new facility in place within this calendar year.

As at 30 September 2025 the Group overdraft facility was drawn down by $887k (September 2024 was nil).

All covenants relating to the BNZ facility have been complied with for the six months ending 30 September 2025.

The related party loan from Edge Group is an open term interest only loan providing working capital in the United Kingdom. Shareholder loans bear interest at AFT 's borrowing rate plus a margin of 1.45%. AFT's reciprocal financing contributions, as the majority shareholder of AFT Pharma UK Limited, are eliminated upon consolidation.

AP

Cash and cash equivalents include cash on hand, deposits held at call with financial institutions and other short-term investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities on the balance sheet.

8. Share Capital

Ordinary shares are classified as equity.

	Unaudited as at 30 Sep 2025 Shares	Audited as at 31 Mar 2025 Shares	Unaudited as at 30 Sep 2025 $'000	Audited as at 31 Mar 2025 $'000
Ordinary share capital	104,866,260	104,866,260	78,240	78,240
Total	**104,866,260**	**104,866,260**	**78,240**	**78,240**

	Unaudited 6 months ended 30 Sep 2025 Shares	Audited 12 months ended 31 Mar 2025 Shares	Unaudited 6 months ended 30 Sep 2024 $'000	Audited 12 months ended 31 Mar 2025 $'000
Share capital at beginning of the year	104,866,260	104,866,260	78,240	78,240
Issue of ordinary shares for exercised share options	-	-	-	-
Total	**104,866,260**	**104,866,260**	**104,866,260**	**78,240**

Ordinary shares

No shares were issued during the period (In the six-month period to September 2024: no shares were issued as a result of staff share options being exercised as detailed below).

Staff share options

No staff share options were exercised in the six-month period to 30 September 2025, and no new options were granted.

9. Dividends per Share

On 4 July 2025 payment of a dividend of 1.8 cents per share or approximately $1.9 million was paid. This was not imputed. In July 2024 a dividend of 1.6 cents per share, or approximately 1.7million, was paid to the ordinary shareholders.

10. Contingent Assets and Liabilities

The Group has provided a guarantee to Investec Limited for the lease premises AFT Pharmaceuticals (AU) Pty Limited occupies in Sydney, Australia. A deposit of AUD$84,000 is held with NAB bank as security for this lease.

The Group has provided a guarantee to Robt Jones Investment Holdings Ltd of $100,000 as security over the leased office premises at 129 Hurstmere Road, Takapuna. Auckland.

The Group placed NZD$75,000 on term deposit with BNZ bank as security for a guarantee issued by BNZ in favour of the NZX.

The High Court of Auckland made judgement in late August 2023 in a case brought against the Company by a former contractor to the Company, PBL Solutions Limited (PBL), in Southeast Asia. In essence the case involved PBL's opportunity to participate in Pascomer drug development opportunities. As part of the judgement the Court ruled AFT is not required to account to PBL for any profit which AFT may earn from the application of Pascomer for treatment of nonorphan conditions such as Port Wine Stain (PWS). PBL appealed this aspect of the judgement and a hearing took place in February 2025. A judgment has yet to be received from that hearing. The group included the appeal as one of its factors in assessing the carrying value of the Pascomer IP, and the valuation indicates sufficient headroom such that a reasonably possible change to the key assumptions is unlikely to result in an impairment of the Pascomer assets. The key assumptions have remained materially the same as those reported in the March 2025 annual report. These include successful clinic trials and registration in the US, Europe, and Australasia; cashflows out to 2043 at a discount rate of 12.5% and for PWS, consistent addressable markets in the US, Europe, and Australasia. The Group continue to assume no growth in the patient base, peak penetration of 2.5% and a success probability of 30%

11. Capital Commitments

The Group has no capital commitments at 30 September 2025 (31 March 2025: nil, 30 September 2024: nil).

12. Financial Risk Management

Managing financial risk

The Group's activities expose it to various financial risks as detailed below.

• Market risk

Management is of the opinion that the Group's exposure to market risk at balance date is defined as:

Risk factor description	Description	Sensitivity
Currency risk	Exposure to changes in foreign exchange rates on assets, liabilities, revenue and expenses	As below
Interest rate risk	Exposure to changes in interest rates on borrowings	As below
Other price risk	No commodity securities are bought, sold or traded	Nil

• Foreign exchange risk

The Group benefits from the use of derivative financial instruments to manage foreign currency exposures. The fair value of forward exchange contracts is calculated by reference to current forward exchange rates at year end and the contract exchange rates, considered level 2 of the fair value hierarchy.

The Group sells and purchases goods and services to and from overseas customers and suppliers in several currencies, primarily AUD, USD, EUR and GBP which exposes the Group to foreign currency risk. The Group manages foreign currency risk through use of derivative arrangements, in particular forward exchange contracts. The exposure is monitored on a regular basis based on Group foreign exchange policies, which allow for up to 50% forward cover out for twelve months. Future revenues from markets outside Australasia will be denominated primarily in USD and EUR which will provide an increasing natural hedge against costs.

In the current period for the six months to 30 September net foreign exchange gains totalled $ 829k (2024: gains $299k). The balance of gains/losses are derived from the restatement of monetary balances at the spot rate on the period-end balance date of 30 September 2025 and settlement of transactions during the period.

In total, the Group had financial assets and liabilities denominated in the following currencies:

	Unaudited 30 Sep 2025		Audited 31 Mar 2025		Unaudited 30 Sep 2024	
Currency	Assets NZD$'000	Liabilities NZD$'000	Assets NZD$'000	Liabilities NZD$'000	Assets NZD$'000	Liabilities NZD$'000
AUD	41,359	3,375	41,353	4,859	30,166	5,934
USD	6,338	1,692	5,412	4,867	3,040	3,227
MYR	839	3	470	1	631	3
GBP	472	24	850	442	1,184	383
EUR	7,274	7,169	5,318	7,637	5,142	5,688
SGD	1,435	55	1,033	30	445	10
CNY	140	-	12	41	79	-
BND	-	-	-	-	-	-
HKD	7	-	3	2	6	3
YEN	-	2	-	9	-	2
CHF	-	-	-	-	-	-
CAD	-	-			1	-

The following forward foreign exchange contracts were held at 30 September 2025:

Forward Foreign Exchange Contracts				
Buy currency	**Buy currency amount $'000**	**Sell amount NZD$'000**	**Buy amount NZD$'000**	**Fair value NZD$'000**
EUR	-	-	-	-
USD	-	-	-	-
Sell currency	**Sell currency amount $'000**	**Buy amount NZD$'000**	**Sell amount NZD$'000**	**Fair value NZD$'000**
AUD	2,600	2,863	2,771	92
Total Asset As at 30 Sep 2025				**92**
Total Liability As at 30 Sep 2025				**-**

The following forward foreign exchange contracts were held at 31 March 2025:

Forward Foreign Exchange Contracts				
Buy currency	**Buy currency amount $'000**	**Sell amount NZD$'000**	**Buy amount NZD$'000**	**Fair value NZD$'000**
EUR	600	1,066	1,140	74
USD	500	816	874	58
Sell currency	**Sell currency amount $'000**	**Buy amount NZD$'000**	**Sell amount NZD$'000**	**Fair value NZD$'000**
AUD	11,400	12,580	12,520	60
Total asset as at 31 March 2025				**192**
Total liability as at 31 March 2025				**-**

The following forward foreign exchange contracts were held at 30 September 2024:

Forward Foreign Exchange Contracts				
Buy currency	**Buy currency amount $'000**	**Sell amount NZD$'000**	**Buy amount NZD$'000**	**Fair value NZD$'000**
EUR	2,950	5,242	5,192	(50)
USD	2,330	3,805	3,660	(145)
GBP				
Sell currency	**Sell currency amount $'000**	**Buy amount NZD$'000**	**Sell amount NZD$'000**	**Fair value NZD$'000**
AUD	17,900	19,701	19,484	216
Total asset as at 30 September 2024				**216**
Total liability as at 30 September 2024				**(195)**

- **Interest rate risk**

Borrowings are at a mixture of floating base rates plus a margin determined by the Group's performance against covenant adherence levels, which exposes the Group to cash flow interest rate risk. There are no specific derivative arrangements to manage this risk.

- **Credit risk**

Financial instruments, which potentially subject the Group to credit risk, principally consist of accounts receivable and cash and cash equivalents. Regular monitoring is undertaken to ensure that the credit exposure remains within the Group's normal terms of trade.

The Group has one significant concentration of credit risk at 30 September 2025, with the largest debtor being AU$ 10.3m (30 September 2024: AU$ 6.1m). The value is stated net of expected rebates. There has been no past experience of default and no indications of default in relation to this debtor.

The Group's cash and short-term deposits are placed with high credit quality financial institutions.

Accordingly, the Group has no significant concentration of credit risk other than bank deposit. At balance date, bank deposits at each financial institution as a percentage of total assets were nil at Bank of New Zealand being in an overdraft position at 30 September 2025 (2024 0.4%), and 4.7% at NAB Bank (2024: 5.5%). The carrying value of financial assets represents the maximum exposure to credit risk.

• Liquidity risk

Liquidity risk is the risk that the Group may encounter difficulty in raising funds at short notice to meet its commitments and arises from the need to borrow funds for working capital. The directors monitor the risk on a regular basis and actively manage the cash available to ensure the net exposure to liquidity risk is minimised.

The liquidity/maturity profile of the liabilities (inclusive of derivative assets and liabilities) is as follows:

30 September 2025 (unaudited)	< 1 year $'000	1-2 years $'000	2-5 years $'000	> 5 years $'000	TOTAL $'000
Trade and other payables	(27,682)	-	-	-	(27,682)
Borrowings	(34,478)	-	-	-	(34,478)
Lease liabilities	(1,078)	(911)	(1,689)	(677)	(4,355)
Derivative instruments (outbound)	(2,771)	-	-	-	(2,771)
Derivative instruments (inbound)	2,863	-	-	-	2,863
Total	**(63,146)**	**(911)**	**(1,689)**	**(677)**	**(66,423)**
31 March 2025 (audited)	**$'000**	**$'000**	**$'000**	**$'000**	**$'000**
Trade and other payables	(33,105)	-	-	-	(33,105)
Borrowings	(2,248)	(27,015)	-	-	(29,263)
Lease liabilities	(1,073)	(948)	(1,772)	(1,271)	(5,064)
Derivative instruments (outbound)	(14,402)	-	-	-	(14,402)
Derivative instruments (inbound)	14,594	-	-	-	14,594
Total	**(36,234)**	**(27,963)**	**(1,772)**	**(1,271)**	**(67,240)**

Fair Values

The carrying values of trade receivables, trade payables and borrowings approximate their fair values because of their short terms to maturity or interest reset dates. Trade receivables are valued net of provision and trade payables are valued at their original amounts by contract.

13. Management of Capital

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern so that it can continue to provide returns to its shareholders and to maintain a strong capital base to support the development of its business. The Group meets these objectives through a mix of equity capital and borrowings. The level and mix of capital are determined by the Group's internal Corporate Governance policies.

Under the BNZ facility, there is a covenant requirement that the facility, comprising an overdraft and letter of credit facility, must not exceed the total of 70% of acceptable debtors plus 50% of acceptable stock. Additional covenants include a requirement for a minimum principal and interest cover ratio, a minimum net leverage ratio and a maximum capital expenditure (capex) and research and development (R&D) ratio. Covenant reporting is required on a quarterly basis. The Group was compliant with all BNZ covenants during the period.

14. Significant Events After Balance Sheet Date

There were no other significant events after balance sheet date.

15. Related Parties

The Group had related party relationships with the following entities:

Related party	Nature of relationship
Atkinson Family Trust	AFT Chief Executive Officer, Hartley Atkinson, is a Trustee / Discretionary Beneficiary of Atkinson Family Trust. AFT Chief of Staff, Marree Atkinson, is a Discretionary Beneficiary of Atkinson Family Trust
Edge Group	Minority shareholder of AFT Pharma UK Limited. Related party loan.

Key management compensation	Unaudited 6 months ended 30 Sep 2025 $'000	Audited 12 months ended 31 Mar 2025 $'000	Unaudited 6 months ended 30 Sep 2024 $'000
Director fees	271	503	243
Executive salaries	904	1,756	878
Short term benefits	233	480	240
Options expense	-	-	-
Key management compensation	**1,408**	**2,739**	**1,362**
Related party loan	**1,468**	**1,083**	**439**

Key management includes external directors, the Chief Executive Officer, the Chief of Staff, the Chief Financial Officer and the Director of International Business Development. These positions are mainly responsible for planning, controlling and directing the activities of the business.

Total remuneration of $150K was paid by the Group to close family members of the key management personnel for individuals that were employed by the Group for the six months to 30 September 2025 (31 March 2025: $264K, 30 September 2024: $67k).

Directory

AFT is a company incorporated with limited liability under the New Zealand Companies Act 1993 (Companies Office registration number 873005).

Registered Offices	Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand. +64 9 488 0232 www.aftpharm.com 113 Wicks Road, North Ryde NSW 2113, Australia. +61 2 9420 0420
Principal Administration Offices	New Zealand: Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand. +64 9 488 0232 Australia: 113 Wicks Road, North Ryde NSW 2113, Australia. +61 2 9420 0420 United Kingdom: 133 Whitechapel High Street, London, UK
Directors – at the date of this Annual Report	Dr Hartley Atkinson Marree Atkinson David Flacks Andrew Lane Dr Ted Witek Allison Yorston
Share Registrar:	Computershare Investor Services Limited Level 2, 159 Hurstmere Road, Takapuna, Auckland 0622, New Zealand. +64 9 488 8777 enquiry@computershare.co.nz Computershare Investor Services Pty Limited, Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067, Australia. +61 3 9415 4083 enquiry@computershare.co.nz
Financial Auditor	Deloitte Limited Deloitte Centre, 1 Queen Street, Auckland 1140, New Zealand. +64 9 303 0700
Greenhouse Gas Auditor	Toitū Envirocare The Former, 87 Albert Street, Auckland Central, Auckland 1010, New Zealand. 0800 366 275
Legal Counsel	Harmos Horton Lusk Level 33, Vero Centre, 48 Shortland Street, Auckland 1140, New Zealand. +64 9 921 4300

Financial Calendar

Financial year end	31 March 2026
Full year results announcement	May 2026
Annual Meeting	August 2026
Half-year end	30 September 2026

Level 1, 129 Hurstmere Road
Takapuna
Auckland 0622
New Zealand
+64 9 488 0232
www.aftpharm.com

AFT *pharmaceuticals*

Working to improve your health

Results for announcement to the market		
AFT Pharmaceuticals Limited		
Reporting Period	6 months to September 30 2025	
Previous Reporting Period	6 months to September 30 2024	
Currency	NZ$	
	Amount (000s)	**Percentage change**
Revenue from continuing operations	$114,942	Up 33%
Total Revenue	$114,942	Up 33%
Net profit/(loss) from continuing operations	$4,737	Up 363%
Total net profit/(loss)	$4,737	Up 363%

Interim/Final Dividend	
Quoted Equity Securities:	
Amount per Quoted Equity Security	$0.01800000
Imputed amount per Quoted Equity Security	No imputation
Record Date	29/06/2025
Dividend Payment Date	04/07/2025

	Current period	**Prior comparable period**
Net tangible assets per Quoted Equity Security	$0.36	$0.26

A brief explanation of any of the figures above necessary to enable the figures to be understood	Accompanying this announcement are the Group's unaudited consolidated financial statements for the six months ended 30 September 2025. These financial statements and the half year results commentary dated 20 November 2025 provide the balance of information requirements in accordance with NZX Listing Rules and Appendix 2. Pursuant to ASX listing rule 1.15.3 AFT Pharmaceuticals Limited confirms that it continues to comply with the rules of its home exchange (NZX Main Board).

Authority for this announcement	
Name of person authorised to make this announcement	Malcolm Tubby
Contact person for this announcement	Malcolm Tubby, Chief Financial Officer, AFT Pharmaceuticals Ltd
Contact phone number	+64 9 488 0232
Contact email address	malcolm.tubby@aftpharm.com
Date of release through MAP	20 November 2025

Unaudited financial statements accompany this announcement.